2连板联环药业：LH-1801项目当前仍处于研发阶段

Core Viewpoint - The company, Lianhuan Pharmaceutical, announced that its stock price has experienced significant fluctuations, but its operations remain normal with no undisclosed major issues [1] Group 1: Company Operations - Lianhuan Pharmaceutical confirmed that its production and operations are normal [1] - The company conducted a self-examination and consulted with its controlling shareholder and actual controller, finding no major adjustments in market environment or industry policies [1] - There are no undisclosed major information that needs to be reported [1] Group 2: Stock Performance - The company's stock price has deviated by more than 20% over three consecutive trading days, indicating abnormal trading fluctuations [1] Group 3: R&D Risks - The company highlighted the R&D risks associated with the LH-1801 project, including uncertainties in clinical data conclusions and significant uncertainties in the Phase III clinical trial and subsequent processes [1]